[
  {
    "ts": "2025-11-19T12:00:00+00:00",
    "headline": "SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK",
    "summary": "GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the",
    "url": "https://finance.yahoo.com/news/scynexis-completes-transfer-brexafemme-drug-120000155.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "0efb0e95-030f-37fd-8a26-3a8388693535",
      "content": {
        "id": "0efb0e95-030f-37fd-8a26-3a8388693535",
        "contentType": "STORY",
        "title": "SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK",
        "description": "",
        "summary": "GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the",
        "pubDate": "2025-11-19T12:00:00Z",
        "displayTime": "2025-11-19T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/817bc585d7c3c4642c78259e4992418f",
          "originalWidth": 3455,
          "originalHeight": 787,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiin9tJ4nnPGqelxu_BrOg--~B/aD03ODc7dz0zNDU1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/817bc585d7c3c4642c78259e4992418f.cf.webp",
              "width": 3455,
              "height": 787,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2ZeIump5hXSJdFzs9dT7dA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/817bc585d7c3c4642c78259e4992418f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/scynexis-completes-transfer-brexafemme-drug-120000155.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/scynexis-completes-transfer-brexafemme-drug-120000155.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SCYX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T11:45:00+00:00",
    "headline": "Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection",
    "summary": "RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve) (MK-8591A-053). The success criterion for the primary efficacy hypothesis, as measured",
    "url": "https://finance.yahoo.com/news/merck-announces-positive-topline-results-114500988.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "e2132413-aa96-3f16-92e9-c3ca7bd1d8cf",
      "content": {
        "id": "e2132413-aa96-3f16-92e9-c3ca7bd1d8cf",
        "contentType": "STORY",
        "title": "Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection",
        "description": "",
        "summary": "RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve) (MK-8591A-053). The success criterion for the primary efficacy hypothesis, as measured",
        "pubDate": "2025-11-19T11:45:00Z",
        "displayTime": "2025-11-19T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/1a5cea47ddf05ad5d0023b0264362f7a",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u_K8Jgono6h8a6WAOiPkvQ--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1a5cea47ddf05ad5d0023b0264362f7a.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Yt4NPjEjDUWw2itQYNDioQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1a5cea47ddf05ad5d0023b0264362f7a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-announces-positive-topline-results-114500988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-announces-positive-topline-results-114500988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T11:30:00+00:00",
    "headline": "European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union",
    "summary": "RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administration and a new pharmaceutical form (solution for injection) of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. KEYTRUDA SC™, as it will be marketed in the European Union (EU), [known as KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.]",
    "url": "https://finance.yahoo.com/news/european-commission-approves-subcutaneous-administration-113000200.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f4253f46-653e-32cc-86f4-2788dfd6b0f0",
      "content": {
        "id": "f4253f46-653e-32cc-86f4-2788dfd6b0f0",
        "contentType": "STORY",
        "title": "European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union",
        "description": "",
        "summary": "RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administration and a new pharmaceutical form (solution for injection) of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. KEYTRUDA SC™, as it will be marketed in the European Union (EU), [known as KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.]",
        "pubDate": "2025-11-19T11:30:00Z",
        "displayTime": "2025-11-19T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/68cd651591fdc81478a19589b3fb0cef",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fW_5jVV4QqSTqxTu18wYJg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/68cd651591fdc81478a19589b3fb0cef.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UswnbiKGi7uLhKt22W6dPw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/68cd651591fdc81478a19589b3fb0cef.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/european-commission-approves-subcutaneous-administration-113000200.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/european-commission-approves-subcutaneous-administration-113000200.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "196170.KQ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]